A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

NCT01316822 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer

Interventions

DRUG: ARRY-382, cFMS inhibitor; oral

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer